--- title: "U.S. Stock Market Midday Update: ADXN Rises 13.78% Without Positive News? Influx of Funds Triggers Abnormal Volatility" type: "News" locale: "en" url: "https://longbridge.com/en/news/296645044.md" description: "Addex Therapeutics rose 13.78%; Eli Lilly rose 1.22%, with a trading volume of USD 1.845 billion; Merck rose 2.36%, with a trading volume of USD 1.434 billion; Johnson & Johnson rose 1.54%, with a trading volume of USD 810 million; Novartis rose 1.94%, with a market capitalization of USD 302.7 billion" datetime: "2026-08-21T18:58:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296645044.md) - [en](https://longbridge.com/en/news/296645044.md) - [zh-HK](https://longbridge.com/zh-HK/news/296645044.md) generator: "portal-rs" --- # U.S. Stock Market Midday Update: ADXN Rises 13.78% Without Positive News? Influx of Funds Triggers Abnormal Volatility **U.S. Stock Market Midday Update** Addex Therapeutics, up 13.78%, with increased trading volume and no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** Eli Lilly up 1.22%. Based on recent news, 1. On August 19, Eli Lilly's stock price rose 5.3%, reaching an all-time high with a market capitalization of $1.21 trillion. The core driver of the company's performance comes from the GLP-1 diabetes and weight loss drug portfolio, with Q2 revenue and profit significantly exceeding market expectations, and the company simultaneously raised its full-year performance guidance. Source: Daily Economic News 2. On August 20, Eli Lilly signed a collaboration agreement with Amplitude Therapeutics to jointly develop a trans-amplification RNA vaccine candidate for infectious diseases. The financial terms of this collaboration were not disclosed, and the two companies will initially focus on vaccine projects with high unmet medical needs. Source: Viewpoint Network 3. On August 19, Eli Lilly's stock price rose 3.6%, closing at $1225.73. The company's strong financial performance prompted several analysts to raise their target prices. BMO Capital Markets raised Eli Lilly's target price to $1400, and Wells Fargo raised its target price to $1330. Source: MarketBeat The innovative drug sector in the pharmaceutical industry is welcoming investment opportunities, with a dense release of clinical data throughout the year. Merck up 2.36%. Based on recent key news: 1. On August 19, Merck and Moderna jointly announced that their personalized mRNA cancer vaccine achieved significant success in Phase III clinical trials, reducing the risk of melanoma recurrence. Following the announcement, Merck's stock price hit an all-time high, rising by 9.6%. 2. On August 20, UBS raised Merck's target price from $142 to $170, reflecting market confidence in its future growth potential. Analysts believe that Merck's new therapies will provide new markets for future growth. 3. On August 21, Morgan Stanley raised Merck's target price from $39 to $89, upgrading its rating from "Hold" to "Overweight," given the success of the personalized melanoma vaccine trial, which enhances the company's ability to address the patent cliff facing its blockbuster therapy Keytruda in 2028. The innovative drug sector is performing strongly, with significant capital inflows, though risks need to be monitored. Johnson & Johnson up 1.54%. Based on recent key news: 1. On August 19, Johnson & Johnson faces ongoing mesothelioma lawsuits and risks from state court litigation. The company needs to meet a 95% participation threshold from claimants, and its core innovative drug division faces challenges from biosimilar competition and sluggish growth in the MedTech division, leading to stock price volatility. 2. On August 17, Johnson & Johnson executive Jennifer L. Taubert sold $3.95 million worth of company stock, indicating insider concerns about the company's prospects, further impacting the stock price On August 20, analysts rated Johnson & Johnson as "Moderate Buy," but noted that there are five stocks with greater investment value, which weakened market confidence in Johnson & Johnson. The industry faces competition from biosimilars and sluggish growth in the MedTech sector. **Top Stocks by Market Capitalization in the Industry** Novartis rose by 1.94%. Based on recent key news: 1. On August 19, Novartis presented 10 abstracts at the 2026 European Society of Cardiology Congress, highlighting its role in cardiovascular risk management. This data showcased Novartis's commitment to advancing cardiovascular science, boosting market confidence in its innovation capabilities and driving up the stock price. 2. On August 20, a report from CMB International pointed out that multinational pharmaceutical companies will face a patent cliff in the next three years, prompting companies like Novartis to adjust their strategic layout in China, focusing on deepening and innovating in the domestic market. This strategic adjustment was seen as a positive signal by the market, boosting investor confidence. 3. On August 21, Boehringer Ingelheim established a research and development center in Zhangjiang, Shanghai, marking China's upgrade from an "important market" for multinational pharmaceutical companies to a "key engine of global innovation." This trend highlights the importance of the Chinese market in global pharmaceutical innovation, indirectly benefiting multinational companies like Novartis. Multinational pharmaceutical companies are facing a patent cliff and adjusting their strategic layout ### Related Stocks - [ADXN.US](https://longbridge.com/en/quote/ADXN.US.md) - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) - [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md) - [NVS.US](https://longbridge.com/en/quote/NVS.US.md) ## Related News & Research - [Addex says preclinical study shows mGlu7 inhibitor ADX71743 boosts wakefulness in rats](https://longbridge.com/en/news/292013939.md) - [Addex shareholders approve all board proposals at AGM](https://longbridge.com/en/news/291226787.md) - [ADXN: Net loss widened to CHF 1.7 million in Q1 2026; urgent funding needed beyond July 2026](https://longbridge.com/en/news/290779494.md) - [Addex Reports Robust Preclinical Efficacy for Novel GABAB Modulator in Chronic Cough](https://longbridge.com/en/news/283442653.md) - [Addex Reports Neurosterix On Track To Complete Phase 1 Trial For Schizophrenia Drug NTX-253](https://longbridge.com/en/news/283857819.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**